BioCryst's Orladeyo now available in U.S.
- BioCryst Pharmaceuticals' (NASDAQ:BCRX) oral, once-daily ORLADEYO (berotralstat) is now available for shipment to patients with a prescription in the U.S.
- ORLADEYO was approved by the FDA on December 3, for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adults and pediatric patients 12 years and older.
- Optime Care, the exclusive specialty pharmacy provider has begun shipping today.
- https://seekingalpha.com/news/3644797-biocrysts-orladeyo-now-available-in-u-s
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.